Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Hussein RS, Tantawy W, Abbas YA. MRI assessment of hepatocellular carcinoma after locoregional therapy. Insights Imaging. 2019;10(1):8.
   PubMed Web of Science ®Google Scholar
• Korean Society of Abdominal R. Diagnosis of Hepatocellular Carcinoma with Gadoxetic Acid-Enhanced MRI. 2016 consensus recommendations of the Korean society of abdominal radiology. Korean J Radiol. 2017;18(3):427–443.
   PubMed Web of Science ®Google Scholar
• Hellberg D, Nilsson S. Genital cancer among wives of men with penile cancer. A study between 1958 and 1982. Br J Obstet Gynaecol. 1989;96(2):221–225.
   PubMedGoogle Scholar
• Chen S, Wang C, Cui A, et al. Development of a genetic and clinical data-based (GC) risk score for predicting survival of hepatocellular carcinoma patients after tumor resection. Cell Physiol Biochem. 2018;48(2):491–502.
   PubMedGoogle Scholar
• Zhang R, Zhang Z, Liu Z, et al. Adoptive cell transfer therapy for hepatocellular carcinoma. Front Med. 2019;13(1):3–11.
   PubMed Web of Science ®Google Scholar
• Kaemmerer D, Schindler R, Mussbach F, et al. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer. 2017;17(1):896.
   PubMedGoogle Scholar
• Vazquez-Carretero MD, Carvajal AE, Serrano-Morales JM, et al. The Synaptojanins in the murine small and large intestine. J Bioenerg Biomembr. 2016;48(6):569–579.
   PubMed Web of Science ®Google Scholar
• Malecz N, McCabe PC, Spaargaren C, et al. Synaptojanin 2, a novel Rac1 effector that regulates clathrin-mediated endocytosis. Curr Biol. 2000;10(21):1383–1386.
   PubMed Web of Science ®Google Scholar
• Rusk N, Le PU, Mariggio S, et al. Synaptojanin 2 functions at an early step of clathrin-mediated endocytosis. Curr Biol. 2003;13(8):659–663.
   PubMed Web of Science ®Google Scholar
• Chuang YY, Tran NL, Rusk N, et al. Role of synaptojanin 2 in glioma cell migration and invasion. Cancer Res. 2004;64(22):5275–8271.
   Web of Science ®Google Scholar
• Chuang Y, Xu X, Kwiatkowska A, et al. Regulation of synaptojanin 2 5ʹ-phosphatase activity by Src. Cell Adh Migr. 2012;6(6):518–525.
   PubMed Web of Science ®Google Scholar
• Artym VV, Zhang Y, Seillier-Moiseiwitsch F, et al. Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res. 2006;66(6):3034–3043.
   PubMed Web of Science ®Google Scholar
• Abram CL, Seals DF, Pass I, et al. The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells. J Biol Chem. 2003;278(19):16844–16851.
   PubMed Web of Science ®Google Scholar
• Baldassarre M, Pompeo A, Beznoussenko G, et al. Dynamin participates in focal extracellular matrix degradation by invasive cells. Mol Biol Cell. 2003;14(3):1074–1084.
   PubMed Web of Science ®Google Scholar
• Du Q, Guo X, Zhang X, et al. SYNJ2 variant rs9365723 is associated with colorectal cancer risk in Chinese Han population. Int J Biol Markers. 2016;31(2):e138–143.
   PubMed Web of Science ®Google Scholar
• Lim LC, Looi ML, Zakaria SZ, et al. Identification of differentially expressed proteins in the serum of colorectal cancer patients using 2D-DIGE proteomics analysis. Pathol Oncol Res. 2016;22(1):169–177.
   PubMed Web of Science ®Google Scholar
• Ben-Chetrit N, Chetrit D, Russell R, et al. Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Sci Signal. 2015;8(360):ra7.
   PubMed Web of Science ®Google Scholar
• Zhang L, Luo B, Dang YW, et al. The clinical significance of endothelin receptor type B in hepatocellular carcinoma and its potential molecular mechanism. Exp Mol Pathol. 2019;107:141–157.
   PubMed Web of Science ®Google Scholar
• Gerbes A, Zoulim F, Tilg H, et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018;67(2):380–388.
   PubMed Web of Science ®Google Scholar
• Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017;173:106–117.
   PubMed Web of Science ®Google Scholar
• Mettlen M, Chen PH, Srinivasan S, et al. Regulation of clathrin-mediated endocytosis. Annu Rev Biochem. 2018;87:871–896.
   PubMed Web of Science ®Google Scholar
• Kaksonen M, Roux A. Mechanisms of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2018;19(5):313–326.
   PubMed Web of Science ®Google Scholar
• Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005;6(2):112–126.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558.
   PubMed Web of Science ®Google Scholar
• Monoranu CM, Huang B, Zangen IL, et al. Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomas. Cancer Genet Cytogenet. 2008;182(1):18–26.
   PubMedGoogle Scholar
• Rossi MR, Hawthorn L, Platt J, et al. Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis. Cancer Genet Cytogenet. 2005;161(2):97–103.
   PubMedGoogle Scholar
• Qin T, Liu H, Song Q, et al. The screening of volatile markers for hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2247–2253.
   PubMed Web of Science ®Google Scholar
• Ganne-Carrie N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol. 2019;70(2):284–293.
   PubMed Web of Science ®Google Scholar
• De Mattia E, Cecchin E, Guardascione M, et al. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. World J Gastroenterol. 2019;25(29):3870–3896.
   PubMed Web of Science ®Google Scholar
• Wang W, Smits R, Hao H, et al. Wnt/beta-catenin signaling in liver cancers. Cancers (Basel). 2019;11(7):926.
   PubMed Web of Science ®Google Scholar
• Zhou K, Outcomes FC. Quality of life of systemic therapy in advanced hepatocellular carcinoma. Cancers (Basel). 2019;11(6):861.
   PubMed Web of Science ®Google Scholar
• Berger ER, Iyengar NM. Obesity and energy balance considerations in triple-negative breast cancer. Cancer J. 2021;27(1):17–24.
   PubMed Web of Science ®Google Scholar
• Bachmann M, Rossa A, Antoniazzi G, et al. Synthesis and cellular effects of a mitochondria-targeted inhibitor of the two-pore potassium channel TASK-3. Pharmacol Res. 2021;164:105326.
   PubMed Web of Science ®Google Scholar
• Tripodi F, Badone B, Vescovi M, et al. Methionine supplementation affects metabolism and reduces tumor aggressiveness in liver cancer cells. Cells. 2020;9(11):2491.
   PubMed Web of Science ®Google Scholar
• Escalona E, Munoz M, Pincheira R, et al. Cytosolic NUAK1 enhances ATP production by maintaining proper glycolysis and mitochondrial function in cancer cells. Front Oncol. 2020;10:1123.
   PubMed Web of Science ®Google Scholar
• Kim I, Kim M, Park MK, et al. The disubstituted adamantyl derivative LW1564 inhibits the growth of cancer cells by targeting mitochondrial respiration and reducing hypoxia-inducible factor (HIF)-1alpha accumulation. Exp Mol Med. 2020;52(11):1845–1856.
   PubMed Web of Science ®Google Scholar
• Symons M, Settleman J. Rho family GTPases: more than simple switches. Trends Cell Biol. 2000;10(10):415–419.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lou Y, Bai XL, et al. Immunometabolism: a novel perspective of liver cancer microenvironment and its influence on tumor progression. World J Gastroenterol. 2018;24(31):3500–3512.
   PubMed Web of Science ®Google Scholar
• Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5(1):e189.
   PubMedGoogle Scholar
• Todisco S, Convertini P, Iacobazzi V, et al. TCA cycle rewiring as emerging metabolic signature of hepatocellular carcinoma. Cancers (Basel). 2019;12(1):68.
   PubMed Web of Science ®Google Scholar
• El-Ashmawy NE, El-Bahrawy HA, Shamloula MM, et al. Biochemical/metabolic changes associated with hepatocellular carcinoma development in mice. Tumour Biol. 2014;35(6):5459–5466.
   PubMedGoogle Scholar
• Tseng PL, Wu WH, Hu TH, et al. Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect. Sci Rep. 2018;8(1):3081.
   PubMedGoogle Scholar
• Huang C, Freter C. Lipid metabolism, apoptosis and cancer therapy. Int J Mol Sci. 2015;16(1):924–949.
   PubMed Web of Science ®Google Scholar
• Liu Q, Luo Q, Halim A, et al. Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer. Cancer Lett. 2017;401:39–45.
   PubMed Web of Science ®Google Scholar
• Ramos AR, Elong Edimo W, Phosphoinositide EC. 5-phosphatase activities control cell motility in glioblastoma: two phosphoinositides PI(4,5)P2 and PI(3,4)P2 are involved. Adv Biol Regul. 2018;67:40–48.
   PubMedGoogle Scholar
• Wang AW, Wang YJ, Zahm AM, et al. The dynamic chromatin architecture of the regenerating liver. Cell Mol Gastroenterol Hepatol. 2020;9(1):121–143.
   PubMed Web of Science ®Google Scholar
• Barrera LO, Li Z, Smith AD, et al. Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. Genome Res. 2008;18(1):46–59.
   PubMed Web of Science ®Google Scholar
• Eun HS, Cho SY, Lee BS, et al. Profiling cytochrome P450 family 4 gene expression in human hepatocellular carcinoma. Mol Med Rep. 2018;18(6):4865–4876.
   PubMed Web of Science ®Google Scholar
• Eun HS, Cho SY, Lee BS, et al. Cytochrome P450 4A11 expression in tumor cells: a favorable prognostic factor for hepatocellular carcinoma patients. J Gastroenterol Hepatol. 2019;34(1):224–233.
   PubMed Web of Science ®Google Scholar
• Gao J, Wang Z, Wang GJ, et al. From hepatofibrosis to hepatocarcinogenesis: higher cytochrome P450 2E1 activity is a potential risk factor. Mol Carcinog. 2018;57(10):1371–1382.
   PubMed Web of Science ®Google Scholar
• DeWaal D, Nogueira V, Terry AR, et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun. 2018;9(1):446.
   PubMedGoogle Scholar